- Home
- INMB
as 06-30-2025 1:32pm EST
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products includeINKmune, INBO3, XPro1595, LIVNate, and others.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | BOCA RATON |
| Market Cap: | 176.5M | IPO Year: | 2019 |
| Target Price: | $24.33 | AVG Volume (30 days): | 5.5M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.94 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.00 - $11.64 | Next Earning Date: | 07-31-2025 |
| Revenue: | $50,000 | Revenue Growth: | -61.83% |
| Revenue Growth (this year): | 82.14% | Revenue Growth (next year): | 28750.98% |
Latest INmune Bio Inc. Common stock News
INMB Breaking Stock News: Dive into INMB Ticker-Specific Updates for Smart Investing
MT Newswires
11 hours ago
Traders Assess Potential US-Canada Trade Deal, Lifting US Equity Futures Pre-Bell
MT Newswires
11 hours ago
INmune Bio's XPro Fails to Meet Primary Cognitive Endpoint in Phase 2 Alzheimer's Trial; Shares Fall
Investing.com
12 hours ago
INmune Bio stock plummets after mixed Phase 2 Alzheimer’s trial results
MT Newswires
12 hours ago
Top Premarket Decliners
GlobeNewswire
12 hours ago
INmune Bio Reports Key Findings from Phase 2 MINDFuL Trial of XPro™ in Early Alzheimer’s Disease
Simply Wall St.
2 days ago
INmune Bio's US$24m Market Cap Fall Books Insider Losses
MT Newswires
3 days ago
INmune Bio to Raise $19 Million in Direct Offering to Institutional Investors
GlobeNewswire
3 days ago
INmune Bio, Inc. Announces Approximately $19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Compare INMB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "INMB INmune Bio Inc. Common stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.